PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
TI  - Empagliflozin Improves Glycemic Parameters and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus
DP  - 2013 Sep 01
TA  - MD Conference Express
PG  - 16--17
VI  - 13
IP  - 11
4099  - http://mdc.sagepub.com/content/13/11/16.short
4100  - http://mdc.sagepub.com/content/13/11/16.full
AB  - Patients with type 2 diabetes mellitus (T2DM) who are treated with empagliflozin, a sodium glucose cotransporter 2 inhibitor, as monotherapy or add-on antihyperglycemic therapy experience clinically meaningful improvements in glycemic parameters and several cardiovascular risk factors. This article discusses the results of a pooled analysis of four randomized, placebo-controlled Phase 3 trials in which the effects of 24 weeks of empagliflozin were evaluated in 2477 T2DM patients.